- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 14, 2023
Highlights
- Market Cap
- $229.87M
- Enterprise Value
- $193.32M
- EPS (TTM)
- -$1.34
- EBITDA (TTM)
- -$48.74M
- Year Range
- $4.50 - $11.41
- Target Price
- $8.00
- ROA (TTM)
- -40.38%
- ROE (TTM)
- -42.47%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SGMT Performance Chart
Sagimet Biosciences Inc. (SGMT) is up 19.3% since the beginning of the year. At $7 per share, SGMT is trading 38.1% below its 52-week high of $11.
Loading charts...
Returns By Period
Sagimet Biosciences Inc. (SGMT) has returned 19.26% so far this year and -15.55% over the past 12 months.
Sagimet Biosciences Inc.
- 1D
- -0.56%
- 1M
- -0.42%
- YTD
- 19.26%
- 6M
- 17.47%
- 1Y
- -15.55%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
SGMT Monthly Returns History
Based on dividend-adjusted daily data since Jul 14, 2023, SGMT's average daily return is +0.23%, while the average monthly return is +2.80%. At this rate, an investment would double in approximately 2.1 years.
Historically, 39% of months were positive and 61% were negative. The best month was Jun 2025 with a return of +114.7%, while the worst month was Oct 2023 at -58.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.
On a daily basis, SGMT closed higher 46% of trading days. The best single day was Jan 22, 2024 with a return of +170.1%, while the worst single day was Feb 6, 2024 at -30.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.22% | 0.71% | -8.49% | 53.68% | -9.22% | -3.16% | 19.26% | ||||||
| 2025 | -2.22% | -15.57% | -12.25% | 5.83% | 2.90% | 114.65% | 14.04% | -13.58% | -8.66% | 24.20% | -15.26% | -18.01% | 31.56% |
| 2024 | 74.91% | -35.34% | -11.58% | -28.04% | 36.67% | -35.83% | -1.75% | -8.33% | -10.06% | 85.92% | 10.49% | -20.91% | -16.97% |
| 2023 | 2.90% | -24.26% | -27.15% | -58.41% | 4.37% | 41.88% | -65.03% |
Benchmark Metrics
Sagimet Biosciences Inc. has an annualized alpha of 24.32%, beta of 2.07, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since July 14, 2023.
- This stock participated in 311.61% of S&P 500 Index downside but only 157.90% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 24.32%
- Beta
- 2.07
- R²
- 0.04
- Upside Capture
- 157.90%
- Downside Capture
- 311.61%
Return for Risk
Risk / Return Rank
SGMT ranks 37 for risk / return — below 37% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Sagimet Biosciences Inc. (SGMT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SGMT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.96 | ||
| Sortino ratioReturn per unit of downside risk | -2.05 | ||
| Omega ratioGain probability vs. loss probability | 1.04 | 1.32 | -0.28 |
| Calmar ratioReturn relative to maximum drawdown | -0.28 | 2.46 | -2.74 |
| Martin ratioReturn relative to average drawdown | -0.45 | 10.92 | -11.37 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Sagimet Biosciences Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Sagimet Biosciences Inc. was 89.69%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Sagimet Biosciences Inc. drawdown is 61.67%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -89.69%Apr 2025 | 1y 2mo | — | 2y 5moJan 2024 - now |
2023 bear market2023 | -86.30%Nov 2023 | 3mo 11d | 2mo 10d | 5mo 21dAug 2023 - Jan 2024 |
2023 pullback2023 | -6.60%Jul 2023 | 1d | 8d | 9dJul 2023 - Aug 2023 |
2023 pullback2023 | -2.12%Jul 2023 | 0s | 4d | 4dJul 2023 - Jul 2023 |
Drawdown Indicators
| SGMT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.69% | -56.78% | -32.91% |
Max Drawdown (1Y)Largest decline over 1 year | -55.57% | -9.10% | -46.47% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -61.67% | -3.21% | -58.46% |
Average DrawdownAverage peak-to-trough decline | -65.83% | -10.71% | -55.12% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 34.28% | 2.04% | +32.24% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Sagimet Biosciences Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Sagimet Biosciences Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SGMT in comparison with other companies in the Biotechnology industry. Currently, SGMT has a P/B value of 2.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SGMT
Add Sagimet Biosciences Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SGMT